We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-negative breast cancer patient who later was administrated with a PARP inhibitor for 2 months. We demonstrated in cell and mouse models that, compared to the wild-type, (1) c.403G>A mutant cell lines were more sensitive to irradiation, a DNA damage agent, and a PARP inhibitor; (2) c.403G>A mutation inhibited interaction between BARD1 and RAD51 (but not BRCA1); and (3) c.403G>A mutant mice were hypersensitive to ionizing radiation. Our study shed lights on the clinical interpretation of rare germline mutations of BARD1.
CITATION STYLE
Zheng, Y., Li, B., Pan, D., Cao, J., Zhang, J., Wang, X., … Shi, L. (2021). Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient. Breast Cancer Research, 23(1). https://doi.org/10.1186/s13058-021-01428-5
Mendeley helps you to discover research relevant for your work.